← Back to Clinical Trials
Recruiting NCT05264051
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Trial Parameters
Condition Liver Diseases
Sponsor University of Chicago
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,200
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-04-18
Completion 2027-03-01
Brief Summary
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Eligibility Criteria
Inclusion Criteria: * Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated Exclusion Criteria: * \<18 yrs. of age
Related Trials
NCT04556019
Results of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit
View Trial →
NCT05733832
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
View Trial →
NCT05264051
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
View Trial →